A good deal rests on the race to develop a weight-loss pill that will widen the market beyond today's injectable "fat jabs".

Novo Nordisk (NYSE: NVO) is a Danish pharma heavyweight currently trading at undervalued levels, presenting an attractive ...

The US Food and Drug Administration (FDA) granted approval for a second treatment for metabolic dysfunction-associated ...

Trump administration says it wants to review national security implications of $1.5bn project that is 80% complete ...

Analysts found the agency's decision to cancel the meeting encouraging. Elsewhere, the Novo Holdings-owned CDMO cut about 350 ...

Drugmaker Novo Nordisk (NVO) will offer a reduced 2025 yearly bonus to its employees in Denmark due to the company’s lowered ...

Novo Nordisk (NVO) will be forced to lower employee bonuses in its home country, Denmark, as the company doubles down on a ...

Novo Nordisk A/S’s slower growth will crimp employee bonuses in the Ozempic maker’s home market of Denmark as it ramps up a ...

US President Donald Trump has backed down from setting high tariffs on pharmaceuticals and semiconductors imported from the ...

For the first time, Denmark is establishing production of microchip wafers at the leading standard. This makes Denmark a ...

Novo Nordisk raced to meet demand for its weight-loss drug Wegovy and almost doubled its workforce over five years. Now, the ...

After a 20% stock plunge, Denmark's prized drugmaker triggers fears over jobs, confidence, and consumer spending.